Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of SKL24741 in Healthy Subjects
NCT04505397Phase 1Completed
- Sponsor
- SK Life Science, Inc.
- Start
- Feb 2020
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SKL24741 in epilepsy, sponsored by SK Life Science, Inc. Primary endpoints: Incidence of treatment-emergent adverse events, Clinically significant laboratory assessments and 5 more. Started Feb 2020; status: completed.
02
Drugs
SKL24741
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT04505397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04505397.